Sean McClain, Founder & CEO, founded AbSci in 2011 with a vision to transform traditional biomanufacturing. AbSci is a leading synthetic biology company focused on redefining protein biomanufacturing and drug discovery – making protein production as simple as DNA synthesis through our revolutionary Protein Printing™ technology. Sean has spent his career investigating and developing technologies that drive down drug costs, speed up drug development, and enable the manufacture of next-generation biotherapeutics that would otherwise not make it to market. Sean developed AbSci’s patented Protein Printing technology™ which combines the power of E. coli SoluPro® with a cutting-edge synthetic biology platform for generation of high-diversity strain libraries and high-throughput screening assays to deliver unprecedented titers of complex biologics with superior product quality. Under Sean’s leadership AbSci has grown to more than 67 employees, raised more than $100M in capital, and has established partnerships with industry-leading pharmaceutical companies for the development of biomanufacturing technologies for life-saving drugs.
He is an alumnus of the University of Arizona where he studied Biochemistry and Molecular Biology. Sean has been recognized as part of the 2019 Forbes 30 Under 30 cohort in Science and named as an Entrepreneur Of The Year 2020 Pacific Northwest Region Award Winner. Sean also serves as a board member for the Oregon Bioscience Association, the Oregon Bioscience Incubator and OTRDI and Life Science Washington.